Fortis Healthcare Limited reported a strong financial performance for the quarter ended September 30, 2025, with consolidated net profit rising 82% year-on-year to ₹321 crore, compared with ₹176.5 crore in the same period last year. The growth was driven by solid operational performance across both the hospital and diagnostics segments.
Revenue and Operating Performance
- Revenue: ₹2,331.4 crore (up 17.3% YoY)
- EBITDA: ₹557 crore (up 28% YoY)
- EBITDA Margin: 24% (vs 22% in Q2 FY25)
The company attributed the improvement to higher patient volumes, an increase in elective and complex surgeries, and continued cost optimization initiatives.
Segment Highlights
Hospital Business: The hospital division remained the key growth contributor, supported by rising inpatient admissions, improved case mix, and expansion in specialized medical services.
Diagnostics Business: The diagnostics arm delivered steady performance, aided by network expansion and strong demand for preventive and wellness testing packages.
Corporate Update
In a separate development, IHH Healthcare Berhad, the majority shareholder of Fortis Healthcare, announced the completion of its mandatory open offers for both Fortis Healthcare Ltd and Fortis Malar Hospitals Ltd. The completion marks a key milestone in IHH’s continued expansion and consolidation within the Indian healthcare market.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.